Welcome to our dedicated page for Curis SEC filings (Ticker: CRIS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Curis, Inc. (CRIS) SEC filings page brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, including Form 8-K current reports and related exhibits. These filings provide detailed information on Curis’s financing transactions, licensing and royalty arrangements, asset sales, and Nasdaq listing status, as well as references to its clinical development activities for emavusertib (CA-4948).
Curis’s Form 8-K filings describe material definitive agreements such as securities purchase agreements for registered direct offerings, concurrent private placements, and a PIPE financing involving Series B convertible non-redeemable preferred stock and multiple series of warrants. The filings outline the number and type of securities offered, exercise prices, beneficial ownership limitations, and associated registration rights agreements that govern the resale of shares issuable upon conversion or exercise.
Filings also cover royalty and asset transactions, including the Royalty Interest Purchase Agreement related to Erivedge royalties and the subsequent sale of Curis’s interest in Curis Royalty LLC, which included the Erivedge intellectual property and license agreement. In connection with this sale, Curis reported that it would no longer be entitled to revenues under the Erivedge license and that the liability related to the sale of future royalties would be extinguished, with pro forma financial information provided in an amended Form 8-K.
Investors can review Nasdaq listing and compliance disclosures in Curis’s 8-K reports, where the company discusses notices of non-compliance with the market value of listed securities requirement, its request for a hearing before a Nasdaq panel, and an exception period granted to regain compliance. Additional 8-K items address results of operations and financial condition, prospectus supplements under a shelf registration statement, and corporate slide presentations used in investor meetings.
On Stock Titan, these SEC filings are supplemented with AI-powered summaries that highlight key terms, timelines, and potential implications. Users can quickly identify financing structures, changes in royalty streams, and listing risk factors, while still having access to the full underlying documents for deeper review.
Curis Inc. director Kenneth I. Kaitin reported an open-market purchase of 10,000 shares of Curis common stock at $0.5487 per share. After this transaction, his direct ownership increased to 11,407 shares, indicating a meaningful addition relative to his prior holdings.
CURIS INC filed a Schedule 13G reporting a shared beneficial ownership position of 4,025,992 shares, equal to 9.9% of the outstanding common stock. The reporting persons are Stonepine Capital Management, LLC; Stonepine Capital, L.P.; Stonepine GP, LLC; and Jon M. Plexico, filing jointly.
The filing states the calculation is based on 39,978,693 shares outstanding as of March 20, 2026. It also discloses warrants to acquire 10,000,002 shares that are subject to a 9.99% beneficial ownership limitation. Voting and dispositive power are reported as shared for the 4,025,992 shares; sole voting/dispositive power is reported as 0 for each reporting person.
Curis, Inc. is a biotechnology company focused almost entirely on developing emavusertib (CA-4948), an oral IRAK4/FLT3 inhibitor for hematologic cancers including PCNSL, CLL and AML. Emavusertib has Orphan Drug Designation in the U.S. for PCNSL, AML and MDS, and in Europe for PCNSL.
The company highlights substantial financial strain. As of December 31, 2025, it held $5.1 million in cash and cash equivalents and subsequently raised about $18.6 million net in a January 2026 PIPE financing. Management states there is substantial doubt about Curis’s ability to continue as a going concern and that significant additional capital will be required to fund development and operations.
Curis may need equity financings, collaborations or strategic alternatives, including asset sales or a sale of the company, and acknowledges potential outcomes such as dissolution or bankruptcy if funding cannot be secured. In November 2025, it sold its Erivedge royalty entity, ending revenue from the Genentech collaboration. As of March 20, 2026, there were 39,978,693 common shares outstanding, and Curis also notes the risk of Nasdaq delisting if listing standards are not maintained.
CURIS INC CDO Jonathan B. Zung converted preferred stock into common shares. On March 20, 2026, he converted 50 shares of Series B Convertible Preferred Stock into 66,667 shares of common stock for no additional cash consideration. Following the conversion, he holds 66,667 common shares directly.
Curis Inc. Chief Medical Officer Ahmed Hamdy converted preferred stock into common shares. On March 20, 2026, 50 shares of Series B Convertible Preferred Stock were converted into 66,667 shares of common stock for no additional consideration, leaving no Series B Preferred outstanding for him and 66,667 common shares held directly.
CURIS INC CFO Diantha Duvall converted preferred stock into common shares. On March 20, 2026, 50 shares of Series B Convertible Preferred Stock automatically converted into 66,666 shares of Common Stock for no additional consideration, increasing her direct common stock holdings to 77,707 shares.
Each share of Series B Preferred Stock converts into 1,333.33 common shares under the company’s Certificate of Designations and is subject to specified beneficial ownership limitations. This filing reflects an internal capital structure change for the executive rather than an open‑market purchase or sale.
Curis Inc. reported that President & CEO James E. Dentzer converted preferred shares into common stock. On March 20, 2026, he converted 100 shares of Series B Convertible Non-Redeemable Preferred Stock into 133,333 shares of common stock for no additional consideration through an automatic conversion.
After the conversion, Dentzer directly owned 148,730 shares of Curis common stock. Each Series B preferred share converted into 1,333.33 common shares, consistent with the terms described in the related certificate of designations and subject to specified beneficial ownership limitations.
Curis Inc director Marc Rubin converted preferred stock into common shares. On March 20, 2026, he converted 20 shares of Series B Convertible Preferred Stock into 26,667 shares of Common Stock for no additional consideration through an automatic conversion.
Following the conversion, Rubin directly owned 28,108 shares of Curis Common Stock. The preferred shares were originally sold as part of a $1,000.00 "Security" unit that also included Series A, B and C warrants, and converted subject to stated beneficial ownership limitations.
Curis, Inc. reported a sharply improved 2025 bottom line, with full-year net loss narrowing to $7.6 million ($0.58 per share) from $43.4 million in 2024, and fourth-quarter 2025 net income of $19.4 million versus a prior-year loss of $9.6 million. Results were driven largely by a non-cash $27.2 million gain from extinguishing the liability tied to the sale of future Erivedge royalties, after Curis sold its Erivedge-related interests and is no longer entitled to royalty revenues. Research and development and general and administrative expenses both declined year over year. As of December 31, 2025, cash and cash equivalents were $5.1 million with about 12.9 million shares outstanding. A January 2026 PIPE financing provides up to $80.8 million in potential gross proceeds, and Curis estimates its cash, including $20.2 million already received and up to $20.2 million from potential Series B warrant exercises, should fund operations into the second half of 2027. The company also notes it does not have sufficient cash on hand to support current operations for 12 months from the press release date and will require substantial additional capital to advance emavusertib.